|
4basebio PLC - Cambridge, England-based life sciences company - Appoints Richard Bungay as chief financial officer. Bungay will assume the role from July 2026, succeeding David Roth. Bungay previously served as chief executive officer and chief financial officer of Diurnal Group PLC, the Cardiff, Wales-based pharma company, and he currently serves as a non-executive director of Chroma Therapeutics Ltd, the Birmingham, England-based biotechnology company. Amy Walker, 4basebio chief executive officer, says: ‘Richard has a long and accomplished career in the industry... we are thrilled that he has decided to join 4basebio.’ Separately, Alexander Link and Alan Malus, non-executive directors of 4basebio, will step down effective May 31, 2026. Heikki Lanckreit will succeed Alexander Link, while Cornel Chiriac will replace Alan Malus, subject to regulatory approval. Current stock price: 420.00 pence 12-month change: down 63% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
